| Patient | Martin Luther |
|---|---|
| Date of birth | 1982-11-19 |
| Identifiers | MRN HR-RE004-SYN; SSN (made up) 000-04-3892 |
| Document date | 2026-09-22 |
| Author | Ottilie Brandt-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review of Ménière disease, depression and the passed stone. [S]
Professor Luther returns six weeks after the consultation. He has had one attack since then, of about two hours, ten days before his preventive visit, and none in the three weeks since. He keeps sodium down at home and has cut coffee to a cup a day. Between attacks he feels slightly unsteady when he turns quickly or walks in the dark. The MRI was done last week. The stone he passed nine days after his sick visit has been analyzed. He has taken hydrochlorothiazide and sertraline 50 mg daily; the loose stools on starting sertraline have settled. He has attended five therapy sessions and has begun to plan small pleasant activities each day. His sleep is better, and he has no thoughts of harming himself. [S]
| Element | Detail |
|---|---|
| Attacks | One two-hour attack in six weeks; none in the last three weeks |
| Balance | Slight unsteadiness on quick turns and in the dark |
| Medicines | Hydrochlorothiazide 25 mg; sertraline 50 mg for five weeks |
| Therapy | Five CBT sessions |
| Safety | No suicidal ideation |
| System | Result | Finding |
|---|---|---|
| Ears, nose, mouth, and throat | Positive | Tinnitus quieter; fullness only before the last attack |
| Neurological | Positive | Mild unsteadiness on quick turns; one headache without dizziness |
| Genitourinary | Negative | No flank pain or blood in the urine since the stone passed |
| Musculoskeletal | Negative | No joint pain or swelling |
| Psychiatric | Positive | Mood better; sleep seven hours; PHQ-9 10 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Meclizine 25 mg tablet, one by mouth up to every 8 hours during a severe vertigo attack only, for no more than 3 days at a time | every 8 hours as needed during a severe attack, at most 3 days at a time | Oral route | 2026-07-28 | active | S |
| Naproxen 500 mg tablet, one by mouth twice daily with food for up to 7 days for stone pain | twice daily with food for up to 7 days | Oral route | 2026-08-25 to 2026-09-01 | completed | S |
| Tamsulosin 0.4 mg capsule, one by mouth daily for up to 4 weeks or until the stone passes | once daily until the stone passes | Oral route | 2026-08-25 to 2026-09-03 | completed | S |
| Hydrochlorothiazide 25 mg tablet, one by mouth each morning | once daily in the morning | Oral route | 2026-08-11 | active | S |
| Sertraline 25 mg tablet, one by mouth each morning for one week | once daily in the morning | Oral route | 2026-08-11 to 2026-08-18 | completed | S |
| Sertraline 50 mg tablet, one by mouth each morning | once daily in the morning | Oral route | 2026-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-22 | Body height | 175 | cm | S |
| 2026-09-22 | Body weight | 85.1 | kg | S |
| 2026-09-22 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 2026-09-22 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-22 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-09-22 | Heart rate | 72 | /min | S |
| 2026-09-22 | Respiratory rate | 14 | /min | S |
| 2026-09-22 | Body temperature | 36.7 | Cel | S |
| 2026-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-22 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-22 | Potassium [Moles/volume] in Serum or Plasma | 3.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-22 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-22 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-22 | Calcium [Mass/volume] in Serum or Plasma | 10 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-09-22 | Urate [Mass/volume] in Serum or Plasma | 7.4 | mg/dL | 3.7-8 mg/dL | Normal | S |
| 2026-09-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 96 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-09-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 10 | {score} | S |
Vital signs recorded on 2026-09-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Blood pressure 122/78, pulse 72; weight 85.1 kg |
| Neurological | No nystagmus; head impulse test normal; tandem gait slightly unsteady; Romberg steady on a firm surface, sways on foam with eyes closed |
| Abdomen | No costovertebral angle tenderness |
| Psychiatric | Brighter, reactive affect; no suicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent attacks of spinning vertigo for about three months, the worst twelve days ago, lasting hours, with roaring tinnitus, fullness and muffled hearing in the left ear and nausea, the tinnitus persisting between attacks; with low mood, poor sleep and loss of interest; cause not established at intake: an inner-ear disorder suspected, with vestibular migraine, vestibular schwannoma and posterior circulation stroke to be excluded and depression to be assessed; otology consultation requested | resolved | confirmed | R42 | S — Synthetic presenting problem anchored to his documented attacks of April and July 1527; superseded by the diagnoses at the second visit. |
| Ménière disease of the left ear, definite (AAO-HNS 2020 and Bárány Society criteria), with low-frequency sensorineural hearing loss and persistent tinnitus in the left ear; vestibular migraine considered and judged unlikely as the main cause; vestibular schwannoma excluded by MRI | active | confirmed | H81.02 | S — Synthetic modern diagnosis made at the otology consultation, linked to his documented attacks and to the retrospective diagnosis of Ménière disease (R). |
| Major depressive disorder, recurrent, moderate (DSM-5-TR), with low mood, poor sleep, loss of interest, guilt and fatigue for about two months, after earlier periods of spiritual crisis and low mood; no suicidal ideation | active | confirmed | F33.1 | S — Synthetic modern diagnosis linked to his documented Anfechtungen and low periods; not a claim that he was so diagnosed; the retrospective psychiatric readings are disputed (R). |
| Urinary stone disease: one stone passed spontaneously last year after severe pain; stone type and metabolic risk not yet known at intake | active | confirmed | Z87.442 | S — Synthetic modern problem anchored to his documented first stone in 1526. |
| Right distal ureteral stone, 5 mm, at the ureterovesical junction, with mild right hydronephrosis and renal colic; no infection; kidney function normal; managed with naproxen and tamsulosin; passed nine days later; resolved | resolved | confirmed | N20.1 | S — Synthetic acute problem anchored to his documented recurrent stones; this episode is not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Vertigo attack diary: number, duration, hearing, tinnitus, fullness, headache | Every visit | Completed today | One two-hour attack in six weeks, none in three weeks; one headache without vertigo; Dizziness Handicap Inventory 36 (Dizziness Handicap Inventory in the notes; no LOINC code used) |
| Imaging | MRI of the internal auditory canals with gadolinium | Once, to exclude a retrocochlear lesion with asymmetric hearing loss | Completed today | No vestibular schwannoma or other lesion |
| Laboratory | Sodium, potassium, creatinine and calcium on a thiazide with an SSRI | Two to four weeks after starting, then every three to six months | Completed today | Sodium 137 and potassium 3.9 mmol/L two weeks after starting, drawn at the sick visit; today sodium 136, potassium 3.7 mmol/L, creatinine 1.0 mg/dL, calcium 10.0 mg/dL, glucose 92 mg/dL |
| Laboratory | Uric acid on a thiazide in a stone former | Baseline, then with the 24-hour urine | Completed today | 7.4 mg/dL, from 6.9; no gout |
| Examination | Balance between attacks | Every visit | Completed today | Mild unsteadiness on tandem gait and on foam with eyes closed |
| Referral | Vestibular rehabilitation for chronic imbalance | When imbalance persists between attacks | Referred | Referred to a vestibular physical therapist today |
| Medication safety | Vestibular suppressant use | Every visit | Completed today | One meclizine dose in six weeks |
| Self-management | Sodium, caffeine and alcohol limits | Every visit | Completed today | Salt cut at home, not when dining out; one coffee a day; beer unchanged |
| Imaging | Renal ultrasound after stone passage | Once after passage | Completed today | No hydronephrosis and no remaining stones |
| Laboratory | Stone analysis | Each stone retrieved | Completed today | Calcium oxalate monohydrate 80 percent, calcium phosphate 20 percent (reported in text; no observation stored) |
| Laboratory | 24-hour urine for a recurrent stone former | About six weeks after the stone passed; then within six months of starting treatment | Ordered | Kit given; to be collected before the next visit |
| Survey | PHQ-9 | At least monthly during acute treatment | Completed today | 10, from 15 at intake |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit | Completed today | No suicidal ideation, intent or plan; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Completed today | Done at the sick visit two weeks after starting and at the preventive visit: loose stools for a few days only; no activation |
| Self-management | Psychotherapy attendance | Weekly | Completed today | Five CBT sessions attended |
Goal progress:
Guideline basis: Clinical Practice Guideline: Ménière's Disease (2020); Medical Management of Kidney Stones: AUA Guideline (2014); Surgical Management of Stones: American Urological Association/Endourological Society Guideline, Part I (2016); Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: 24-hour urine before the next visit. Review in five weeks with a repeat audiogram. Next scheduled visit 2026-10-27: thirteen-week review: attacks, repeat audiogram, mood, and the 24-hour urine for stone prevention. [S]